Your browser doesn't support javascript.
loading
Migration in last decade to high-risk prostate cancer after radical prostatectomy.
Patard, P-M; Roumiguié, M; Prudhomme, T; Doumerc, N; Thoulouzan, M; Gamé, X; de la Taille, A; Rischmann, P; Soulié, M; Salomon, L; Beauval, J-B.
Afiliação
  • Patard PM; Department of urology, andrology and renal transplantation, CHU Rangueil, Paul-Sabatier university, 1, avenue J Poulhès, 31059 Toulouse cedex, France. Electronic address: pm.patard@gmail.com.
  • Roumiguié M; Department of urology, andrology and renal transplantation, CHU Rangueil, Paul-Sabatier university, 1, avenue J Poulhès, 31059 Toulouse cedex, France. Electronic address: roumiguie_mathieu@yahoo.fr.
  • Prudhomme T; Department of urology, andrology and renal transplantation, CHU Rangueil, Paul-Sabatier university, 1, avenue J Poulhès, 31059 Toulouse cedex, France. Electronic address: prudhomme-thomas@hotmail.fr.
  • Doumerc N; Department of urology, andrology and renal transplantation, CHU Rangueil, Paul-Sabatier university, 1, avenue J Poulhès, 31059 Toulouse cedex, France. Electronic address: doumerc.n@chu-toulouse.fr.
  • Thoulouzan M; Department of urology, andrology and renal transplantation, CHU Rangueil, Paul-Sabatier university, 1, avenue J Poulhès, 31059 Toulouse cedex, France. Electronic address: thoulouzan.m@chu-toulouse.fr.
  • Gamé X; Department of urology, andrology and renal transplantation, CHU Rangueil, Paul-Sabatier university, 1, avenue J Poulhès, 31059 Toulouse cedex, France. Electronic address: gamexavier@gmail.com.
  • de la Taille A; Department of urology, Henri-Mondor Hospital, Assistance-Publique Hôpitaux de Paris, 51, avenue du Maréchal de Lattre-de-Tassigny, 94010 Créteil, France. Electronic address: adelataille@hotmail.com.
  • Rischmann P; Department of urology, andrology and renal transplantation, CHU Rangueil, Paul-Sabatier university, 1, avenue J Poulhès, 31059 Toulouse cedex, France. Electronic address: rischmann.p@chu-toulouse.fr.
  • Soulié M; Department of urology, andrology and renal transplantation, CHU Rangueil, Paul-Sabatier university, 1, avenue J Poulhès, 31059 Toulouse cedex, France. Electronic address: soulie.m@chu-toulouse.fr.
  • Salomon L; Department of urology, Henri-Mondor Hospital, Assistance-Publique Hôpitaux de Paris, 51, avenue du Maréchal de Lattre-de-Tassigny, 94010 Créteil, France. Electronic address: laurent.salomon@aphp.fr.
  • Beauval JB; Department of urology, andrology and renal transplantation, CHU Rangueil, Paul-Sabatier university, 1, avenue J Poulhès, 31059 Toulouse cedex, France. Electronic address: jbbeauval@gmail.com.
Prog Urol ; 29(1): 29-35, 2019 Jan.
Article em En | MEDLINE | ID: mdl-30337057
ABSTRACT

OBJECTIVE:

There is controversy around prostate cancer (PCa) screening through the use of PSA, due to the risk of overtreatment. The current trend observed in various European and American studies is a decrease in the number of radical prostatectomy (RP) in low-risk PCa and an increase for intermediate or locally advanced diseases. The objective of this study was to observe the migration of the pathological stages from radical prostatectomy (RP) over 10 years in France through 2 French centers.

METHODS:

It was a multicentric retrospective study, where all the RP realized in 2 French tertiary centers, in a laparoscopic or retropubic approach for each of the years 2005, 2010 and 2015 were included. Preoperative data (age, PSA, clinical stage, number of positive biopsies, Gleason biopsy score) and postoperative data (pTNM, pathological Gleason score (pGS)) were analyzed and compared.

RESULTS:

In all, 1282 RP were realized (503 in 2005, 403 in 2010, 376 in 2015). Respectively between 2005, 2010, 2015 the average number of positive biopsy increased significantly from 2.30 vs. 2.88 vs. 5.3 (P=0.0001). The distribution of D'Amico's risk evolves with time low-risk 49.9 vs. 44.4 vs. 15.7% (P=0.0001); intermediate risk 40.95 vs. 43.92 vs. 64.1% (P=0.0001) and high-risk 9.15 vs. 11.66 vs. 20.2% (P=0.0001) between 2005, 2010 and 2015 respectively. pGS evolved to higher score with SG<7 22.8 vs. 29.9 vs. 7.1% et SG≥7 77.2 vs. 70.1 vs. 92.9% (P=0.001). Also, pTNM increased to non-organ-confined disease pT2 66.9 vs. 51.9 vs. 48.7%; pT3 33.1 vs. 48.1 vs. 51.3% (P=0.0001).

CONCLUSION:

This study showed a change in the management of PCa since new recommendations from medical authorities about PSA screening and evolving of conservative treatment. Number of RP increase for higher risk PCa. This change corresponds to better patient selection for RP decrease for low-risk and increase for high-risk organ-confined disease. LEVEL OF EVIDENCE 3.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Prostatectomia / Neoplasias da Próstata Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Prostatectomia / Neoplasias da Próstata Idioma: En Ano de publicação: 2019 Tipo de documento: Article